Gossamer Bio

May 12, 2020

•

Mar 31, 2020

Gossamer Bio Q1 2020 Earnings Report

Announced financial results for the first quarter and provided a corporate update.

Key Takeaways

Gossamer Bio announced the completion of the interim analysis of the LEDA study of GB001 and topline results from the Phase 1b study of GB004 in patients with active mild-to-moderate ulcerative colitis. Cash, cash equivalents and marketable securities totaled $346 million as of March 31, 2020.

GB001 interim analysis of LEDA trial in moderate-to-severe eosinophilic asthma completed.

GB001 intellectual property estate strengthened with issuance of new patent by USPTO covering lysine salt drug substance forms.

GB004 completed successful Phase 1b in ulcerative colitis; Phase 2 trial planned to commence in 2020.

Cash, cash equivalents and marketable securities totaled $346 million as of March 31, 2020.

Research and Development Expenses

$41.4M

General and Administrative Expenses

$10.7M